IL115039A - Spiroazabicyclic compounds, their preparation and pharmaceutical compositions containing them - Google Patents

Spiroazabicyclic compounds, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL115039A
IL115039A IL11503995A IL11503995A IL115039A IL 115039 A IL115039 A IL 115039A IL 11503995 A IL11503995 A IL 11503995A IL 11503995 A IL11503995 A IL 11503995A IL 115039 A IL115039 A IL 115039A
Authority
IL
Israel
Prior art keywords
spiroazabicyclic
compounds
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL11503995A
Other languages
English (en)
Other versions
IL115039A0 (en
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9417084A external-priority patent/GB9417084D0/en
Priority claimed from GBGB9504627.2A external-priority patent/GB9504627D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL115039A0 publication Critical patent/IL115039A0/xx
Publication of IL115039A publication Critical patent/IL115039A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL11503995A 1994-08-24 1995-08-23 Spiroazabicyclic compounds, their preparation and pharmaceutical compositions containing them IL115039A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417084A GB9417084D0 (en) 1994-08-24 1994-08-24 Compounds useful in therapy
GBGB9504627.2A GB9504627D0 (en) 1995-03-08 1995-03-08 Compounds for use in therapy

Publications (2)

Publication Number Publication Date
IL115039A0 IL115039A0 (en) 1995-12-08
IL115039A true IL115039A (en) 2001-08-26

Family

ID=26305509

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11503995A IL115039A (en) 1994-08-24 1995-08-23 Spiroazabicyclic compounds, their preparation and pharmaceutical compositions containing them

Country Status (33)

Country Link
US (2) US5902814A (fr)
EP (1) EP0777671B1 (fr)
JP (1) JP3708962B2 (fr)
KR (1) KR100366331B1 (fr)
CN (2) CN1056846C (fr)
AR (1) AR031828A2 (fr)
AT (1) ATE192157T1 (fr)
AU (1) AU690735B2 (fr)
BR (1) BR9508751A (fr)
CA (1) CA2196995C (fr)
CZ (1) CZ289512B6 (fr)
DE (1) DE69516524T2 (fr)
DK (1) DK0777671T3 (fr)
EE (1) EE03399B1 (fr)
EG (1) EG24222A (fr)
ES (1) ES2145922T3 (fr)
FI (1) FI112868B (fr)
GR (1) GR3033878T3 (fr)
HU (1) HUT77352A (fr)
IL (1) IL115039A (fr)
IS (1) IS1852B (fr)
MX (1) MX9701292A (fr)
NO (1) NO307707B1 (fr)
NZ (1) NZ292289A (fr)
PL (1) PL183933B1 (fr)
PT (1) PT777671E (fr)
RU (1) RU2148058C1 (fr)
SA (1) SA95160370B1 (fr)
SK (1) SK282366B6 (fr)
TR (1) TR199501053A2 (fr)
TW (1) TW397837B (fr)
UA (1) UA54375C2 (fr)
WO (1) WO1996006098A1 (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
JP4564135B2 (ja) * 1999-07-26 2010-10-20 住友化学株式会社 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶
AU2001241056A1 (en) * 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
EP1317460A4 (fr) * 2000-08-28 2005-04-20 Univ Colorado State Res Found Composes contenant un fragment d'oxazolidinone et utilisations
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
JP2005510482A (ja) * 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP2005522457A (ja) * 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
JP4750421B2 (ja) * 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CN1829721A (zh) * 2003-07-08 2006-09-06 阿斯利康(瑞典)有限公司 对α7烟碱乙酰胆碱受体具有亲和力的螺[1－氮杂二环[2.2.2]辛烷－3,5’－噁唑烷]－2’－酮衍生物
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
JP2007530586A (ja) 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法
MX2007006743A (es) * 2004-12-15 2007-07-09 Astrazeneca Ab Ligandos del receptor de acetilcolina nicotinica.
CN101124012B (zh) 2004-12-27 2012-09-05 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病的装置
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
WO2006071184A1 (fr) * 2004-12-28 2006-07-06 Astrazeneca Ab Modulateurs de type arylsulfonamide
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
RU2326787C2 (ru) * 2005-11-09 2008-06-20 Сергей Федорович Бокарев Способ управления крылом, помещенным в текучую среду, при его взаимодействии с этой средой и устройство для его осуществления
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
WO2008028903A2 (fr) 2006-09-04 2008-03-13 Neurosearch A/S Compositions pharmaceutiques
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102008015999B4 (de) 2008-03-27 2011-04-21 Novar Gmbh Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage
WO2009146030A1 (fr) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Méthodes et systèmes de réduction d’une inflammation par neuromodulation de l’activité des lymphocytes t
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US7863291B2 (en) * 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
CN102131791B (zh) 2008-06-20 2014-12-24 阿斯利康(瑞典)有限公司 二苯并硫杂氮杂*衍生物及其用途
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
LT2889033T (lt) 2008-11-19 2018-07-10 Forum Pharmaceuticals Inc. Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
WO2011056573A1 (fr) 2009-10-28 2011-05-12 Bristol-Myers Squibb Company Composés azabicycliques en tant que ligands du récepteur alpha-7 nicotinique d'acétylcholine
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
EP3461481A1 (fr) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Procédés de maintien, de traitement ou d'amélioration de la fonction cognitive
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
WO2014202999A1 (fr) 2013-06-21 2014-12-24 Takeda Cambridge Limited Dérivés de 1-sulfonyl pipéridine utilisés en tant que modulateurs des récepteurs de la prokinéticine
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (fr) 2015-02-03 2016-08-11 Setpoint Medical Corporation Appareil et procédé de rappel, d'incitation ou d'alerte d'un patient ayant un stimulateur implanté
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255B1 (fr) 2016-01-20 2025-12-31 Setpoint Medical Corporation Microstimulateurs implantables et systèmes de recharge par induction
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405107B1 (fr) 2016-01-20 2023-04-12 Setpoint Medical Corporation Commande de stimulation vagale
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10661112B2 (en) 2016-07-25 2020-05-26 Tonal Systems, Inc. Digital strength training
US11745039B2 (en) 2016-07-25 2023-09-05 Tonal Systems, Inc. Assisted racking of digital resistance
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
WO2019036470A1 (fr) 2017-08-14 2019-02-21 Setpoint Medical Corporation Test de dépistage pour stimulation du nerf vague
US10617903B2 (en) 2017-10-02 2020-04-14 Tonal Systems, Inc. Exercise machine differential
US10335626B2 (en) 2017-10-02 2019-07-02 Tonal Systems, Inc. Exercise machine with pancake motor
US10486015B2 (en) 2017-10-02 2019-11-26 Tonal Systems, Inc. Exercise machine enhancements
US10589163B2 (en) 2017-10-02 2020-03-17 Tonal Systems, Inc. Exercise machine safety enhancements
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
WO2021236977A1 (fr) 2020-05-21 2021-11-25 The Feinstein Institutes For Medical Research Systèmes et méthodes de stimulation du nerf vague
US11285355B1 (en) 2020-06-08 2022-03-29 Tonal Systems, Inc. Exercise machine enhancements
US11998804B2 (en) 2021-04-27 2024-06-04 Tonal Systems, Inc. Repetition phase detection
US11878204B2 (en) 2021-04-27 2024-01-23 Tonal Systems, Inc. First repetition detection
WO2022245878A1 (fr) 2021-05-17 2022-11-24 Setpoint Medical Corporation Système d'authentification et d'expiration de paramètre de neurostimulation pour neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028351A (en) * 1971-09-07 1977-06-07 Buskine S.A. Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained
CH601304A5 (fr) * 1974-02-12 1978-07-14 Buskine Sa
SU495310A1 (ru) * 1974-03-05 1975-12-15 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Хинуклидил-3-диарал(гетерил) карбинолы, про вл ющие антигистаминную, антисеротониновую и антиаллергическую активность и способ их получени
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
GB8816299D0 (en) * 1988-07-08 1988-08-10 Merck Sharp & Dohme Therapeutic agents
IL97726A (en) * 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
US5137895A (en) * 1991-04-29 1992-08-11 A. H. Robins Company, Incorporated 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols

Also Published As

Publication number Publication date
ES2145922T3 (es) 2000-07-16
PL183933B1 (pl) 2002-08-30
JP3708962B2 (ja) 2005-10-19
FI112868B (fi) 2004-01-30
JPH10504561A (ja) 1998-05-06
IS1852B (is) 2003-02-21
PT777671E (pt) 2000-08-31
US5902814A (en) 1999-05-11
EE9700039A (et) 1997-08-15
CN1284505A (zh) 2001-02-21
GR3033878T3 (en) 2000-11-30
TW397837B (en) 2000-07-11
RU2148058C1 (ru) 2000-04-27
CA2196995A1 (fr) 1996-02-29
HK1010370A1 (en) 1999-06-17
EG24222A (en) 2008-11-10
HUT77352A (hu) 1998-03-30
CZ289512B6 (cs) 2002-02-13
FI970762L (fi) 1997-02-24
CA2196995C (fr) 2008-05-13
ATE192157T1 (de) 2000-05-15
CN1056846C (zh) 2000-09-27
AU690735B2 (en) 1998-04-30
CN1159808A (zh) 1997-09-17
FI970762A0 (fi) 1997-02-24
EP0777671A1 (fr) 1997-06-11
DE69516524D1 (de) 2000-05-31
UA54375C2 (uk) 2003-03-17
TR199501053A2 (tr) 1996-06-21
WO1996006098A1 (fr) 1996-02-29
SA95160370B1 (ar) 2006-06-04
PL318760A1 (en) 1997-07-07
IL115039A0 (en) 1995-12-08
NO307707B1 (no) 2000-05-15
MX9701292A (es) 1997-05-31
BR9508751A (pt) 1997-08-12
AR031828A2 (es) 2003-10-08
CZ39297A3 (en) 1997-12-17
CN1099419C (zh) 2003-01-22
KR100366331B1 (ko) 2003-04-10
EE03399B1 (et) 2001-04-16
NZ292289A (en) 1998-05-27
NO970800L (no) 1997-02-21
AU3401895A (en) 1996-03-14
SK282366B6 (sk) 2002-01-07
NO970800D0 (no) 1997-02-21
SK21697A3 (en) 1997-09-10
US6051581A (en) 2000-04-18
DK0777671T3 (da) 2000-07-24
DE69516524T2 (de) 2001-01-18
IS4424A (is) 1997-02-03
EP0777671B1 (fr) 2000-04-26

Similar Documents

Publication Publication Date Title
IL115039A (en) Spiroazabicyclic compounds, their preparation and pharmaceutical compositions containing them
IL113389A0 (en) 1,4-Benzodiazepine compounds, pharmaceutical compositions containing them, their preparation and use
IL112227A0 (en) Compounds, their preparation and pesticidal compositions containing them
IL121236A0 (en) Cycloalkano-pyridines their preparation and pharmaceutical compositions containing them
HUP9603495A2 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, pharmaceutical compositions containing the same and process for their preparation
IL110159A0 (en) Diaryl compounds, their preparation and pharmaceutical compositions containing them
IL119994A0 (en) 2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazolidinones their preparation and pharmaceutical compositions containing them
IL106353A0 (en) Unsymmetrical mono-3-nitro-bis-naphthalimides,their preparation and pharmaceutical compositions containing them
IL122618A0 (en) Substituted imidazolylacetonitrile compounds their preparation and pharmaceutical compositions containing them
HUP0002272A3 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
IL115905A0 (en) Sordarin derivatives their preparation and pharmaceutical compositions containing them
IL112443A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
IL98499A0 (en) Aminobenzodiazepines,their preparation and pharmaceutical compositions containing them
IL108703A0 (en) Substituted azolone derivatives, their preparation and pharmaceutical compositions containing them
IL100364A0 (en) Benzodiazepinones,their preparation and pharmaceutical compositions containing them
IL113123A0 (en) Mono- or bicyclic compounds, their preparation and pharmaceutical compositions containing them
IL111011A0 (en) Bisbenzimidazole compounds, their preparation and pharmaceutical compositions containing them
HUP9801386A3 (en) Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them
IL113366A0 (en) 1,5-benzodiazepine compounds, their preparation and use, and pharmaceutical compositions containing them
IL112936A0 (en) Quinolone - and - naphthyridone - carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
IL108800A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
IL116190A (en) Eleutherobin, analogs thereof and pharmaceutical compositions containing them
IL115272A0 (en) Asp-pallidipin pharmaceutical compositions containing the same and processes for the preparation thereof
IL114623A0 (en) Substituted triazolylmethylphenylnaph-thyridones their preparation and pharmaceutical compositions containing them
HU9603388D0 (en) New taxoids, preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees